Phase 3 Recruiting Network
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in diff…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT03937635
Sites in Utah: - American Fork Hospital / Huntsman Intermountain Cancer Center — American Fork, Utah
- Sandra L Maxwell Cancer Center — Cedar City, Utah
- Logan Regional Hospital — Logan, Utah
- Intermountain Medical Center — Murray, Utah
- McKay-Dee Hospital Center — Ogden, Utah
Phase 3 Recruiting Network
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of c…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04566328
Sites in Utah: - Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexam…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05552222
Sites in Utah: - Utah Cancer Specialists — Salt Lake City, Utah
- Huntsman Cancer Institute — Salt Lake City, Utah
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple m…
Sponsor: Celgene
NCT ID: NCT05519085
Sites in Utah: - Utah Cancer Specialists — Salt Lake City, Utah
Phase 3 Recruiting Industry
The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, inclu…
Sponsor: Kite, A Gilead Company
NCT ID: NCT06413498
Sites in Utah: - Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah
- LDS Hospital — Salt Lake City, Utah
Phase 3 Recruiting Industry
The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dex…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06208150
Sites in Utah: - Huntsman Cancer Institute — Salt Lake City, Utah
Phase 3 Recruiting Industry
This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, …
Sponsor: AstraZeneca
NCT ID: NCT07391657
Sites in Utah: - Research Site — Salt Lake City, Utah
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT ID: NCT06615479
Sites in Utah: - Huntsman Cancer Institute — Salt Lake City, Utah
Phase 2 Recruiting Academic/Other
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE:…
Sponsor: American Society of Clinical Oncology
NCT ID: NCT02693535
Sites in Utah: - Cedar City Hospital, SW Cancer Clinic, Sandra Maxwell Cancer Center — Cedar City, Utah
- Intermountain Healthcare — Salt Lake City, Utah
- Dixie Regional Medical Center-River Road Campus — St. George, Utah
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT ID: NCT06297226
Sites in Utah: - LDS Hospital — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Academic/Other
This phase I/II trial tests the safety, side effects, best dose, and effectiveness of iberdomide in combination with belantamab mafodotin and dexamethasone in treating patients with multiple myeloma (MM) that has come back after a period o…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06232044
Sites in Utah: - Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Industry
This trial is a Phase 1b/2, open-label, multicenter study of AZD0120, a CD19/BCMA dual CAR T-cell therapy, in adult subjects with relapsed/refractory multiple myeloma.
Sponsor: AstraZeneca
NCT ID: NCT05850234
Sites in Utah: - Research Site — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Industry
A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.
Sponsor: Sumitomo Pharma America, Inc.
NCT ID: NCT04988555
Sites in Utah: - Huntsman Cancer Institute — Salt Lake City, Utah
- Intermountain Healthcare — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal translocation t(11;14)…
Sponsor: BeOne Medicines
NCT ID: NCT04973605
Sites in Utah: - Huntsman Cancer Institute — Salt Lake City, Utah
Phase 2 Recruiting Academic/Other
This research study will determine the proportion of patients with lowest minimal residual disease (MRD) response obtainable after receiving 6 cycles of study treatment. Minimal residual disease is multiple myeloma cells below the level of…
Sponsor: University of Alabama at Birmingham
NCT ID: NCT05231629
Sites in Utah: - University of Utah — Salt Lake City, Utah
Phase 2 Recruiting Academic/Other
This is a phase II study where patients will undergo isatuximab and lenalidomide maintenance if they are MRD-positive after Autologous Stem Cell Transplant (ASCT)
Sponsor: University of Illinois at Chicago
NCT ID: NCT05344833
Sites in Utah: - Huntsman Cancer Institute — Salt Lake City, Utah
Phase 2 Recruiting Academic/Other
A randomized placebo controlled, phase 2 study of budesonide in subjects with multiple myeloma undergoing autologous stem cell transplant (ACST). The study includes a run-in period with 20 patients.
Sponsor: University of Utah
NCT ID: NCT05405387
Sites in Utah: - Huntsman Cancer Institute at the University of Utah — Salt Lake City, Utah
Phase 2 Recruiting Academic/Other
Historically, the frailest patients with multiple myeloma are under-represented in clinical trials, and have very high rates of treatment discontinuation, and early treatment mortality. The investigators hypothesize that a go-slow gentle a…
Sponsor: University of Utah
NCT ID: NCT06517017
Sites in Utah: - Huntsman Cancer Institute at the University of Utah — Salt Lake City, Utah
Phase 1 Recruiting Industry
The main purpose of the study is to understand the safety and tolerability of cemsidomide when given along with elranatamab in subjects with relapsed or refractory multiple myeloma. The first part of the study will evaluate different dose …
Sponsor: C4 Therapeutics, Inc.
NCT ID: NCT07280013
Sites in Utah: - Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah
Phase 1 Recruiting Industry
This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to as…
Sponsor: Caribou Biosciences, Inc.
NCT ID: NCT05722418
Sites in Utah: - Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah
Phase 1 Recruiting Industry
Phase 1b, open-label study evaluating the safety, tolerability, pharmacokinetics, preliminary antitumor activity, and pharmacodynamics of OPN-6602 monotherapy and in combination with dexamethasone in subjects with relapsed and/or refractor…
Sponsor: Opna Bio LLC
NCT ID: NCT06433947
Sites in Utah: - Huntsman Cancer Center Institute University of Utah — Salt Lake City, Utah
Phase 1 Recruiting Industry
This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up…
Sponsor: Newave Pharmaceutical Inc
NCT ID: NCT04771572
Sites in Utah: - University of Utah — Salt Lake City, Utah
Recruiting Network
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
Sponsor: Center for International Blood and Marrow Transplant Research
NCT ID: NCT01351545
Sites in Utah: - University of Utah — Salt Lake City, Utah
Recruiting NIH
Background: -Patients who are being evaluated and/or treated at the NIH Clinical Center and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens. Objectives: * To ob…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT00900198
Sites in Utah: - University of Utah — Salt Lake City, Utah
Recruiting Academic/Other
In this multicenter study, we will recruit 400 patients 40 years of age or older at 15 centers with a diagnosis of smoldering multiple myeloma (SMM), a group of patients for whom standard of care is observation not treatment. The main goal…
Sponsor: Tufts Medical Center
NCT ID: NCT06365060
Sites in Utah: - University of Utah, Huntsman Cancer Hospital — Salt Lake City, Utah